International Journal of Thyroidology

Fig. 2.

Download original image
Fig. 2. Evaluation and management of bone health in (A) women and (B) men with differentiated thyroid cancer under TSH suppressive therapy. 1The high-risk group for osteoporosis and fragility fractures includes a previous history of fragility fractures, more than 1 year of amenorrhea in women, having other medical diseases or taking medications that cause osteoporosis. 2Ca/D´╝őOsteoporosis Tx, Treatment for osteoporosis is needed in combination with calcium and vitamin D replacement. 3Ca/D±Osteoporosis Tx, Treatment for osteoporosis can be considered in combination with calcium and vitamin D replacement. Anti-osteoporosis treatment includes anti-resorptive agents (e.g., bisphosphonate) and anabolic agents. Certain types of bisphosphonates (i.e., ibandronate) are not available in men. BMD: bone mineral density, Ca/D: calcium and vitamin D, DTC: differentiated thyroid cancer, DXA: dual-energy X-ray absorptiometry, TSH: thyroid stimulating hormone, Tx: therapy
Int J Thyroidol 2022;15:1-16
© 2022 Int J Thyroidol